Dr. Ruud Coumans, PhD

Director Protein Chemistry at Byondis

Speaker

After obtaining a Ph.D. in supramolecular chemistry in 2006 followed by a brief postdoctoral stay in academia working on self-healing materials, Ruud Coumans started at Syntarga to develop duocarmycin based linker-drugs. After acquisition of Syntarga by Byondis in 2011, he led efforts in the field of protein chemistry and engineering which resulted in a novel site-specific conjugation technology, a dual payload ADC technology and more recently a state-of-the-art antibody masking technology called ByonGuard.